The unmet need of stroke prevention in atrial fibrillation in the Far East and South East Asia

Malaysian Journal of Medical Sciences

Volumn 19, Issue 3, 2012, Pages 1-7

  Guo, Yutao ^a   Lip, Gregory Y H ^b   ApostolaLAkis, Stavros ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillaton; Burden; Far East; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; TICLOPIDINE; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; BLEEDING; CARDIAC FAILURE HYPERTENSION AGE DIABETES AND STROKE SCORE; CHINA; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; FEMALE; GENDER; HEALTH CARE NEED; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; MALAYSIA; MALE; PRACTICE GUIDELINE; SINGAPORE; SOUTH KOREA; STROKE; TAIWAN; THAILAND; THROMBOEMBOLISM; VISUAL ANALOG SCALE;

EID: 84863843800     PISSN: 1394195X     EISSN: 21804303     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648-661.
2. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012.
3. Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, et al. Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: A Japanese multicenter cooperative registry. J Stroke Cerebrovasc Dis. 2010;19(3):190-197.
4. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297-305.
5. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138(5):1093-1100.
6. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182, 678 patients with atrial fibrillation: The Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510.
7. Olsson LG, Swedberg K, Lappas G, Stewart S, Rosengren A. Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006. Int J Cardiol. 2012.
8. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis. Chest. 2012;141(2 Suppl):e531S-e575S.
9. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost. 2012;107(6):1172-1179.
10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
11. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatranetexilate. Thromb Haemost. 2010;104(6):1106-1115.
12. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost. 2010;103(4):833-840.
13. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES, and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011;105(4):574-578.
14. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost. 2010;104(1):45-48.
15. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke: A systematic review and meta-analysis. Thromb Haemost. 2011;106(3):528-538.
16. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. Thromb Haemost. 2011;106(4):739-749.
17. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298-2307.